Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
- 15 March 2022
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 18 (5) , 276-285
Abstract
Diffuse cutaneous systemic sclerosis (dcSSc) is associated with high mortality resulting from early internal-organ involvement. Clinicians therefore tend to focus on early diagnosis and treatment of potentially life-threatening cardiorespiratory and renal disease. However, the rapidly progressive painful, itchy skin tightening that characterizes dcSSc is the symptom that has the greatest effect on patients’ quality of life, and there is currently no effective disease-modifying treatment for it. Considerable advances have been made in predicting the extent and rate of skin-disease progression (which vary between patients), including the development of techniques such as molecular analysis of skin biopsy samples. Risk stratification for progressive skin disease is especially relevant now that haematopoietic stem-cell transplantation is a treatment option, because stratification will inform the balance of risk versus benefit for each patient. Measurement of skin disease is a major challenge. Results from clinical trials have highlighted limitations of the modified Rodnan skin score (the current gold standard). Alternative patient-reported and other potential outcome measures have been and are being developed. Patients with early dcSSc should be referred to specialist centres to ensure best-practice management, including the management of their skin disease, and to maximize opportunities for inclusion in clinical trials.Keywords
This publication has 114 references indexed in Scilit:
- Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosisAnnals of the Rheumatic Diseases, 2011
- HLA–DRB1*0407 and *1304 are risk factors for scleroderma renal crisisArthritis & Rheumatism, 2010
- Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trialRheumatology, 2010
- The 5-D itch scale: a new measure of pruritusBritish Journal of Dermatology, 2009
- A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosisRheumatology, 2009
- Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double‐blind, randomized controlled trialsArthritis & Rheumatism, 2009
- Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosisRheumatology, 2008
- Optical coherence tomography - principles and applicationsReports on Progress in Physics, 2003
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin diseaseAnnals of the Rheumatic Diseases, 2001